

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	24,642	91.9%	20,746	92.4%	1,844	88.7%	1,764	90.1%	121	93.1%	2,792	87.8%
Epidermoid carcinoma ^d (8051-8131)	210	0.8%	166	0.7%	18	0.9%	21	1.1%	-	-	34	1.1%
Adenocarcinoma ^e	22,543	84.1%	19,057	84.8%	1,597	76.9%	1,629	83.2%	109	83.8%	2,511	78.9%
Adenocarcinoma, NOS (8140)	3,456	12.9%	2,841	12.6%	393	18.9%	190	9.7%	-	-	351	11.0%
Papillary adenocarcinoma, NOS (8050,8260)	445	1.7%	385	1.7%	35	1.7%	18	0.9%	-	-	50	1.6%
Clear cell adenocarcinoma (8310,9110)	1,362	5.1%	1,055	4.7%	50	2.4%	246	12.6%	-	-	132	4.1%
Endometrioid carcinoma (8380-8383,8570)	2,596	9.7%	2,201	9.8%	121	5.8%	233	11.9%	-	-	334	10.5%
Cystadenocarcinoma, NOS (8440,8450)	132	0.5%	106	0.5%	16	0.8%	-	-	-	-	18	0.6%
Serous cystadenocarcinoma (8441)	4,945	18.4%	4,236	18.9%	326	15.7%	311	15.9%	33	25.4%	515	16.2%
Papillary serous cystadenocarcinoma (8460-8462)	6,819	25.4%	5,925	26.4%	475	22.9%	361	18.4%	33	25.4%	731	23.0%
Mucinous cystadenocarcinoma (8470-8473)	465	1.7%	390	1.7%	28	1.3%	36	1.8%	-	-	82	2.6%
Mucinous adenocarcinoma (8480,8482)	929	3.5%	740	3.3%	83	4.0%	97	5.0%	-	-	127	4.0%
Mucin-producing adenocarcinoma(8481)	63	0.2%	54	0.2%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,331	5.0%	1,124	5.0%	63	3.0%	127	6.5%	-	-	160	5.0%
Other specific carcinomas ^g	614	2.3%	460	2.0%	113	5.4%	33	1.7%	-	-	90	2.8%
Stromal cell tumor (8620-8631,8650)	391	1.5%	277	1.2%	86	4.1%	21	1.1%	-	-	56	1.8%
Other ^h	223	0.8%	183	0.8%	27	1.3%	-	-	-	-	34	1.1%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,275	4.8%	1,063	4.7%	116	5.6%	81	4.1%	-	-	157	4.9%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	95	0.4%	69	0.3%	-	-	-	-	-	-	19	0.6%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,809	6.7%	1,425	6.3%	194	9.3%	165	8.4%	-	-	339	10.7%
Mullerian mixed tumor (8950-8951,8980)	770	2.9%	659	2.9%	63	3.0%	42	2.1%	-	-	65	2.0%
Teratoma, malignant (9080-9085,9102)	392	1.5%	281	1.3%	51	2.5%	52	2.7%	-	-	129	4.1%
Other	647	2.4%	485	2.2%	80	3.8%	71	3.6%	-	-	145	4.6%
Unspecified (8000-8005)	269	1.0%	221	1.0%	25	1.2%	17	0.9%	-	-	31	1.0%
Total ^d	26,815	100.0%	22,461	100.0%	2,078	100.0%	1,957	100.0%	130	100.0%	3,181	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.